E-mail: satu.mustjoki@helsinki.fi
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
- Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib
- FIRST INTERIM ANALYSIS OF A PAN-EUROPEAN STOP TRIAL USING STANDARDIZED MOLECULAR CRITERIA: RESULTS OF THE EURO-SKI TRIAL
- Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy
- Immunomodulatory Effects of Novel Tyrosine Kinase Inhibitors
- Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile
- Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study
- Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing
- Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study
- Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling
- TREATMENT WITH NILOTINIB IN EARLY CHRONIC PHASE CML–FIRST RESULTS FROM THE ENEST1ST SUB STUDY CAMN107EIC01
